GLP-1 receptor agonists: Overview
What it does
The job the technology does for people, in a short paragraph
GLP-1 receptor agonists are medicines that copy a gut hormone released after meals. They help the body control blood sugar and make people feel full sooner. The first, exenatide, was approved in the United States in 2005 [2]. They are used for type 2 diabetes and obesity, conditions that affect 830 million and more than a billion people [3, 4].
as of 2026-11-11
How it works
The working principle in plain words, step by step
After a meal, cells in the gut release a short protein hormone, GLP-1. It docks on a receptor, a protein on the surface of other cells, like a key in a lock. In the pancreas this tells beta cells to release more insulin when blood sugar is high [1]. It also slows the emptying of the stomach and acts on the brain to reduce appetite [1]. The natural hormone is broken down within minutes, so it cannot work as a medicine [1]. The drugs are peptides changed so that they fit the same receptor but last far longer: exendin-4 from lizard venom, then human GLP-1 with small changes that let it bind to blood proteins and resist breakdown. Semaglutide lasts about 165 hours in the body [1].
as of 2026-11-11
Key figures
The handful of numbers that size it up, each with its unit, year and source
| Figure | Value | Unit | Year | Source |
|---|---|---|---|---|
| People living with obesity, more than | 1 | billion people | – | [3] |
| People living with diabetes | 830 | million people | 2022 | [4] |
| Half-life of semaglutide in the body | 165 | hours | – | [1] |
| Novo Nordisk's reported sales of Wegovy | 79.1 | billion DKK | 2025 | [5] |
| Novo Nordisk's own figure for its share of the world GLP-1 diabetes market by value (IQVIA data, 12 months to November 2025) | 45.8 | % | 2025 | [5] |
as of 2026-11-11. The obesity figure is from WHO's guideline of December 2025, which gives no year for it [3]; the sales and market share are Novo Nordisk's own figures from its 2025 financial report, the share based on IQVIA data for November 2025 and covering GLP-1 diabetes medicines only [5].
Where it is used
The main places and products the technology is found in
- Type 2 diabetes, to help control blood sugar [1]
- Long-term treatment of obesity in adults [3]
- Lowering the risk of heart attack and stroke in some people with heart disease and excess weight [1]
- Primary care clinics, diabetes and obesity services, and pharmacies
as of 2026-11-11
Scale today
How much of it there is now: units in use, made each year and who uses it
- Users
- Novo Nordisk reports that its diabetes and obesity medicines reached 45.6 million patients in 2025 [5]
- Unit
- people
- Year
- 2025
- Note
- The company's own estimate, a 12-month total covering all its diabetes and obesity products, including insulin, so it is only a guide; no world count of GLP-1 users was found.
as of 2026-11-11
Sources
- GLP-1-based therapy for obesity Lasker Foundation (2024 Lasker~DeBakey Clinical Medical Research Award), 2024
- Dr. John Eng to Receive Golden Goose Award The Science Coalition, 2013
- WHO issues global guideline on the use of GLP-1 medicines in treating obesity World Health Organization, 2025
- Diabetes (fact sheet) World Health Organization, 2026
- Financial report for the period 1 January 2025 to 31 December 2025 (company announcement No 4/2026, Form 6-K) Novo Nordisk A/S, filed with the US Securities and Exchange Commission, 2026